TriangleNCT02120157 · OUTCOME
Primary and Secondary Graft Failure
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of graft failure
- Interval / dispersion
- Not reported
- Time frame
- 2 years
What was measured
Incidence (measured as a percentage) of primary and secondary graft failure.
Groups in this outcome
Haploidentical BMT With PTCy for Acute Leukemias and MDS
Patients with AML and MDS: Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV For patients with ALL and lymphoblastic lymphoma: Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days All patients Day 0: Infuse unmanipulated bone marrow Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day Day +30: Assess chimerism and disease status in bone marrow Day +35: Discontinue MMF Day +60: Assess chimerism and disease status in bone marrow Day 180: Discontinue tacrolimus Cyclophosphamide: Chemotherapy administration TBI: Radiation Therapy Busulfan: Chemotherapy Administered Unmanipulated Bone Marrow: Bone Marrow Transplant Tacrolimus: Immunosuppressive Drug Administered Mycophenolate mofetil: Immunosuppressive Drug Administered
| Group | Source count |
|---|---|
| Haploidentical BMT With PTCy for Acute Leukemias and MDS | 32 |
Reported measurements
Primary
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Haploidentical BMT With PTCy for Acute Leukemias and MDS | 16 | Not reported | Not reported | Not reported | Not reported |
Secondary
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Haploidentical BMT With PTCy for Acute Leukemias and MDS | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 16
- title
- Primary
- categories
- measurements
- group Id
- OG000
- value
- 0
- title
- Secondary
- denoms
- counts
- group Id
- OG000
- value
- 32
- units
- Participants
- description
- Incidence (measured as a percentage) of primary and secondary graft failure.
- groups
- description
- Patients with AML and MDS: Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV For patients with ALL and lymphoblastic lymphoma: Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days All patients Day 0: Infuse unmanipulated bone marrow Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day Day +30: Assess chimerism and disease status in bone marrow Day +35: Discontinue MMF Day +60: Assess chimerism and disease status in bone marrow Day 180: Discontinue tacrolimus Cyclophosphamide: Chemotherapy administration TBI: Radiation Therapy Busulfan: Chemotherapy Administered Unmanipulated Bone Marrow: Bone Marrow Transplant Tacrolimus: Immunosuppressive Drug Administered Mycophenolate mofetil: Immunosuppressive Drug Administered
- id
- OG000
- title
- Haploidentical BMT With PTCy for Acute Leukemias and MDS
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 2 years
- title
- Primary and Secondary Graft Failure
- type
- SECONDARY
- unit Of Measure
- percentage of graft failure
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice